H.R. 1503Orange Book Transparency Act of 2020

1 recorded action192 of these members are on the 2026 ballotWhat the measure does Read on Congress.gov

Sponsor: Robin L. Kelly [D-IL-02]
Cosponsors: 13 · 12 Democrats · 1 Republican
Policy area: Health
Committees: Energy and Commerce Committee, Health, Education, Labor, and Pensions Committee
Latest action: Jan 5, 2021 · Became Public Law No: 116-290.

IntroducedMar 5, 2019
Passed the HouseMay 8, 2019
Passed the SenateDec 7, 2020
Sent to the PresidentDec 24, 2020
Became lawJan 5, 2021

What the measure doesCRS summary

This bill modifies requirements for the Food and Drug Administration (FDA) to list and publish drug patent and exclusivity information. Specifically, the FDA must include on its list certain patent information and must specify each drug exclusivity period that has not concluded. The holder of an approved drug application must notify the FDA when a listed patent is invalidated by a court or by the Patent Trial and Appeal Board. The FDA must remove invalidated patents from its list, subject to the 180-day drug exclusivity period.

Written by the nonpartisan Congressional Research Service, describing H.R. 1503 as public Law on Jan 5, 2021. It is not the text of the measure; a later amendment may have changed what it does.

How every member votedHouse roll call 187

House May 8, 2019

On Motion to Suspend the Rules and Pass, as Amended

Orange Book Transparency Act

Passed · Two-thirds required

422 Yea 0 Nay 9 not voting

Crossed both parties No voting member broke with their own party.

Open the official roll call

How the chamber split

One dot per member. Select a seat or a bar to filter the list.

DemocratsRepublicansFilled: YeaRing: NayGrey: not voting or present

By party select a segment to filter

All members431 members

Democratic234 members

Republican197 members

marks half of the votes cast. A party’s majority is the side most of its voting members took.

Cosponsors13 · 12 Democrats · 1 Republican

Signing on is not a vote: a member can cosponsor H.R. 1503 and vote against it. 0 signed when it was filed.

DRaul Ruiz [D-CA-36]Joined Apr 2, 20192026 profile

DBOBBY RUSH [D-IL-01]Joined Apr 2, 2019

DFrank Pallone, Jr. [D-NJ-06]Joined Apr 2, 20192026 profile

DDebbie Dingell [D-MI-12]Joined Apr 2, 20192026 profile

DANNA ESHOO [D-CA-18]Joined Apr 2, 2019

DJoseph Kennedy [D-MA-04]Joined Apr 2, 2019

DDoris O. Matsui [D-CA-06]Joined Apr 2, 20192026 profile

DAngie Craig [D-MN-02]Joined Apr 2, 2019

DYvette D. Clarke [D-NY-09]Joined Apr 4, 20192026 profile

DJefferson Van Drew [D-NJ-02]Joined Apr 4, 20192026 profile

RGREG WALDEN [R-OR-02]Joined Apr 4, 2019

DJanice D. Schakowsky [D-IL-09]Joined Apr 12, 2019

Loading the public record

Who lobbied on H.R. 150366 organizations

Organizations that named H.R. 1503 in a lobbying disclosure. Only those that cited the bill by number appear, so this is a floor, not a full list.

NOVO NORDISK INC.filed by WILLIAMS AND JENSEN, PLLC, NOVO NORDISK INC., TARPLIN, DOWNS & YOUNG, LLC, ALSTON & BIRD LLPIts PAC: Novo Nordisk Inc. PAC

Defense · Health Issues · Medicare/Medicaid · Budget/Appropriations +3 more24 filings · 4th Quarter (Oct 1 - Dec 31) 2020Filing

TRAVERE THERAPEUTICSfiled by ALSTON & BIRD LLP, TRAVERE THERAPEUTICS

Taxation/Internal Revenue Code · Health Issues · Medicare/Medicaid · Pharmacy +2 more16 filings · 4th Quarter (Oct 1 - Dec 31) 2020Filing

KAISER FOUNDATION HEALTH PLAN INCfiled by KAISER FOUNDATION HEALTH PLAN INC.

Defense · Taxation/Internal Revenue Code · Health Issues · Medicare/Medicaid +1 more12 filings · 2nd Quarter (Apr 1 - June 30) 2020Filing

BIOTECHNOLOGY INDUSTRY ORGANIZATIONfiled by TARPLIN, DOWNS & YOUNG, LLC, CAPITOL HILL STRATEGIES, LLC

Pharmacy · Taxation/Internal Revenue Code · Health Issues · Medicare/Medicaid +1 more10 filings · 4th Quarter (Oct 1 - Dec 31) 2020Filing

TEVA PHARMACEUTICALS USA INCfiled by TEVA PHARMACEUTICALS USA, INC.Its PAC: Teva Pharmaceuticals USA Inc. PAC

Health Issues · Trade (domestic/foreign)10 filings · 4th Quarter (Oct 1 - Dec 31) 2020Filing

BAYER CORPORATION (CONSOLIDATED REPORT)

Trade (domestic/foreign) · Agriculture · Civil Rights/Civil Liberties · Energy/Nuclear +11 more9 filings · 4th Quarter (Oct 1 - Dec 31) 2020Filing

BRISTOL-MYERS SQUIBB COMPANYIts PAC: Bristol-Myers Squibb Co. PAC

Health Issues · Trade (domestic/foreign) · Taxation/Internal Revenue Code · Copyright/Patent/Trademark +2 more9 filings · 4th Quarter (Oct 1 - Dec 31) 2020Filing

GARY AND MARY WEST HEALTH INSTITUTE, INCfiled by WAXMAN STRATEGIES

Health Issues9 filings · 4th Quarter (Oct 1 - Dec 31) 2020Filing

PHRMAfiled by TARPLIN, DOWNS & YOUNG, LLC, CAPITOL HILL STRATEGIES, LLC

Medicare/Medicaid · Health Issues · Budget/Appropriations · Pharmacy9 filings · 4th Quarter (Oct 1 - Dec 31) 2020Filing

AMERICAN MEDICAL ASSOCIATIONIts PAC: American Medical Association PAC

Labor Issues/Antitrust/Workplace · Torts · Immigration · Education +7 more8 filings · 4th Quarter (Oct 1 - Dec 31) 2020Filing

322 disclosures name this measure. Retrieved from LDA.gov on 2026-10-05. Senate Office of Public Records cannot vouch for the data or analyses derived from these data after the data have been retrieved from LDA.gov.